Capsule Summary Slidesets

Share

Program Content

Activities

Ifinatamab Deruxtecan in SCLC
Subgroup Analysis of Patients With Refractory SCLC From a Phase I/II Trial Evaluating the Novel ADC Ifinatamab Deruxtecan
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2023

Phase Ib FAVOUR Trial
FAVOUR: Phase Ib Study of Furmonertinib in EGFR Exon 20 Insertion–Positive Locally Advanced or Metastatic NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 14, 2023

HERTHENA-Lung01
HERTHENA-Lung01: Phase II Trial of Patritumab Deruxtecan in Previously Treated EGFR-Mutated Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 14, 2023

DESTINY-Lung02
DESTINY-Lung02: Phase II Trial of Trastuzumab Deruxtecan in Patients With Previously Treated HER2-Mutated Metastatic NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 14, 2023

LUNAR Subgroup Analysis
Tumor Treating Fields + Immune Checkpoint Inhibition in Metastatic NSCLC After Platinum Failure: Phase III LUNAR Subgroup Analysis by PD-L1 Expression
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 14, 2023

FLAURA2: Osi ± CT in EGFR+ NSCLC
FLAURA2: Phase III Trial of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 14, 2023

Phase I/II TRIDENT-1 Update
TRIDENT-1 Update: Phase I/II Study of Repotrectinib in Patients With ROS1 Fusion–Positive Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 15, 2023

AEGEAN Surgical Outcomes
Phase III AEGEAN: Analysis of Surgery-Related Outcomes With Neoadjuvant Durvalumab + CT Followed by Adjuvant Durvalumab in Resectable NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 15, 2023

1L Cemiplimab in Adv NSCLC With Liver Mets
Phase III EMPOWER-Lung 1 and 3: Updated Long-term Subgroup Analysis of Cemiplimab in Newly Diagnosed Advanced NSCLC With Liver Metastases
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 19, 2023

Phase Ib TROPION-Lung04
Phase Ib TROPION-Lung04: Datopotamab Deruxtecan + Durvalumab ± Carboplatin in Advanced/Metastatic NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 20, 2023

Amivantamab in METex14+ NSCLC
Phase I CHRYSALIS Update: Amivantamab in Expanded Cohort of Patients With Advanced NSCLC and MET Exon 14 Skipping Mutations
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 20, 2023

Phase II I-SABR
Phase II I-SABR: Stereotactic Ablative Radiotherapy ± Nivolumab for Untreated Early-Stage or Isolated Lung Parenchymal Recurrent Node-Negative NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 20, 2023

INSIGHT 2 Primary Analysis
Phase II INSIGHT 2: Primary Analysis of Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 20, 2023

Phase II EVOKE-02
Phase II EVOKE-02: First-line Sacituzumab Govitecan + Pembrolizumab in Metastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 20, 2023

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc